Coherus BioSciences is transitioning from a biosimilar-focused company to a specialized innovative oncology firm with a commercial-stage PD-1 inhibitor and a promising immuno-oncology pipeline. The core business leverages regulatory and guideline differentiation in a rare cancer niche to build a fo…
Coherus BioSciences (CHRS) Q1 2025: LOQTORZI Demand Grows 15% Amid Strategic Oncology Focus
Coherus BioSciences completed its strategic pivot to innovative oncology with a 15% rise in LOQTORZI patient demand in Q1 2025, despite transitional salesforce restructuring and prior supply interruptions. The company’s proprietary immuno-oncology pipeline advances with promising clinical signals, positioning Coherus for meaningful data readouts in 2026. Investors should watch for commercialization acceleration and clinical milestones driving future growth.
Summary
- Focused Oncology Transformation: Divestiture of biosimilars completed, sharpening Coherus’ innovative oncology strategy.
- Commercial Momentum Building: LOQTORZI patient demand increased 15% despite salesforce restructuring and inventory adjustments.
- Pipeline Clinical Progress: Early clinical data for CHS-114 and casdozokitug support upcoming pivotal readouts in 2026.
Business Overview
Coherus BioSciences is a commercial-stage innovative oncology company focused on developing and marketing immuno-oncology therapies. Its business model centers on revenue generation from LOQTORZI, an FDA-approved next-generation PD-1 inhibitor for nasopharyngeal carcinoma (NPC), complemented by a proprietary pipeline including CHS-114, a selective anti-CCR8 antibody, and casdozokitug, an IL-27 antagonist. The company recently divested its biosimilar franchise, including UDENYCA, to concentrate resources on oncology innovation.
Performance Analysis
In Q1 2025, LOQTORZI net product sales reached $7.3 million, reflecting a 15% increase in patient demand compared to Q4 2024. This demand growth stemmed from both an expanded number of new accounts initiating treatment and increased treatment duration, particularly among earlier stage patients expected to remain on therapy longer. Despite this demand growth, reported revenue remained flat due to a seasonal inventory drawdown and the tail effects of prior supply interruptions.
Coherus’ continuing operations revenue rose to $7.6 million from $2.3 million a year prior, driven entirely by LOQTORZI volume growth post-launch. Cost of goods sold increased accordingly, while research and development expenses declined 14% year-over-year due to lower co-development costs and headcount reductions, partially offset by increased investment in CHS-114 and casdozokitug. Selling, general and administrative expenses fell 35%, reflecting the absence of a prior year impairment charge and cost savings from divestitures and lower headcount.
- Demand Growth Despite Transition: 15% patient demand increase signals strengthening commercial traction amid salesforce restructuring.
- Cost Discipline Evident: R&D and SG&A reductions align with strategic focus and divestiture-related savings.
- Discontinued Operations Impact: UDENYCA divestiture recognized in discontinued operations, with $483 million upfront cash received post-quarter.
Overall, Coherus is transitioning from a biosimilar-focused entity to a pure-play innovative oncology company, with early commercial progress in LOQTORZI and advancing pipeline programs laying the foundation for future value creation.
Executive Commentary
"With our biosimilar divestitures behind us and our promising innovative oncology business in front of us, we are fully focused on innovative oncology. LOQTORZI growth is now focused on increasing market penetration driven by strong NCCN guidelines and duration of treatment. We project LOQTORZI in NPC alone will grow to about $150 to $200 million annually over the next three years, providing non-dilutive funding for our development pipeline."
Denny Lamphere, Chief Executive Officer
"Following treatment with CHS-114, we observed greater than 50% depletion of CCR8 positive Tregs and a marked increase in tumor infiltrating CD8 T cells, supporting its potential as a combination therapy to overcome PD-1 resistance. We have gained FDA alignment on dosing through a Type D meeting, and are on track for a recommended phase two dose early next year."
Theresa LaValley, Chief Scientific and Development Officer
Strategic Positioning
1. Oncology-Centric Business Model Post-Divestiture
Coherus has completed its divestiture of the UDENYCA biosimilar franchise, receiving $483 million upfront in April 2025, thereby freeing capital and management focus to concentrate on innovative oncology. This shift positions the company as a commercial-stage oncology firm with a proprietary PD-1 inhibitor and a pipeline of immuno-oncology candidates, aiming to build a sustainable, differentiated franchise.
2. LOQTORZI Commercial Expansion Supported by NCCN Guideline Leadership
LOQTORZI is uniquely positioned as the only FDA-approved and NCCN-preferred treatment for recurrent or metastatic nasopharyngeal carcinoma across all lines of therapy. The recent NCCN guideline update to Preferred status with Category 1 designation supports adoption. The salesforce restructuring and territory remapping, while short-term headwinds, aim to optimize execution for steady demand growth and market share capture in a rare but underserved cancer indication.
3. Proprietary Pipeline Advancing with Clinical Validation
CHS-114, a highly selective anti-CCR8 antibody, has demonstrated pharmacologically relevant Treg depletion and immune activation in early clinical trials, including a confirmed partial response in a heavily pretreated head and neck cancer patient. Casdozokitug, an IL-27 antagonist, showed encouraging complete response rates in hepatocellular carcinoma when combined with standard agents. Both programs have pivotal data expected in the first half of 2026, underpinning Coherus’ strategy to develop synergistic immuno-oncology combinations.
4. Efficient Capital Allocation and Cost Management
Post-divestiture, Coherus expects approximately $25 million in annualized savings from headcount reductions and lower SG&A expenses. The company has proactively repurchased $170 million of convertible notes and plans to retire the remaining $60 million, improving its capital structure. R&D spending is being prioritized toward pipeline programs with near-term data catalysts, reflecting disciplined resource allocation aligned with strategic priorities.
5. Partnership-Driven Indication Expansion Strategy
Coherus is pursuing capital-efficient collaborations to expand LOQTORZI’s label beyond NPC, supplying the drug to partners who fund clinical development. This approach mitigates financial risk while broadening the commercial footprint. Ongoing partnerships include pivotal trials in HPV-positive head and neck cancer and small cell lung cancer, positioning LOQTORZI as a preferred PD-1 backbone for combination therapies.
Key Considerations
Coherus is navigating a critical inflection point as it transitions fully into innovative oncology, balancing near-term commercial execution with longer-term pipeline development.
Key Considerations:
- Commercial Momentum Build: LOQTORZI’s 15% patient demand growth despite salesforce changes signals strengthening adoption but requires sustained execution to convert demand into revenue growth.
- Rare Disease Market Dynamics: NPC’s low incidence means adoption ramps steadily as physicians encounter eligible patients, necessitating persistent education and engagement.
- Pipeline Data as Growth Drivers: Upcoming 2026 data readouts for CHS-114 and casdozokitug are pivotal to validate clinical potential and unlock commercial opportunity beyond NPC.
- Cost and Capital Discipline: Divestiture proceeds and note repurchases improve financial flexibility, but ongoing R&D investment must be balanced against cash burn and cash on hand.
- Regulatory Engagement: Positive FDA interactions on dosing and development plans for CHS-114 reduce regulatory risk and support efficient clinical progression.
Risks
Coherus faces risks typical of oncology biopharmaceutical companies, including clinical trial execution uncertainties, regulatory hurdles, and the challenge of commercializing in a rare disease with a limited patient population. The salesforce restructuring and prior supply interruptions have caused transitional headwinds that could delay revenue growth. Additionally, the competitive landscape for PD-1 inhibitors and immuno-oncology agents is intense, necessitating clear differentiation and clinical validation.
Forward Outlook
For Q2 2025, Coherus expects LOQTORZI commercial momentum to accelerate as the salesforce restructure completes, with patient demand and revenue growth resuming pace. The company anticipates reporting the financial impact of the UDENYCA divestiture, including upfront proceeds and related note repurchases.
- Q2 guidance will reflect contributions from LOQTORZI sales and reduced SG&A expenses post-divestiture.
- Full-year 2025 SG&A expenses are projected between $90 million and $100 million, incorporating transaction-related costs and ongoing commercial investments.
Management highlighted that clinical data readouts from CHS-114 and casdozokitug are expected in the first half of 2026, which will be critical milestones for the company’s pipeline advancement and valuation.
Takeaways
Coherus is strategically repositioning as a focused innovative oncology company with an FDA-approved PD-1 inhibitor and a differentiated immuno-oncology pipeline. Early commercial traction for LOQTORZI, evidenced by a 15% increase in patient demand, shows promise despite transitional salesforce changes and inventory adjustments.
- Commercial Execution Is Improving: The completion of salesforce remapping post-divestiture should enable acceleration in LOQTORZI uptake, critical for covering commercial costs and funding pipeline development.
- Pipeline Clinical Data Will Be Key Catalysts: The translational biomarker data and early clinical responses for CHS-114 and casdozokitug support the company’s thesis of overcoming PD-1 resistance and expanding indications, with pivotal data due in 2026.
- Financial Flexibility Enhanced: Divestiture proceeds and debt repurchases improve the balance sheet, but cash burn remains a consideration given ongoing R&D investment and commercialization costs.
Conclusion
Coherus BioSciences’ Q1 2025 results mark a clear strategic inflection as the company exits biosimilars and accelerates its focus on innovative oncology. LOQTORZI’s growing patient demand and promising pipeline data position Coherus to build a sustainable oncology franchise, with operational execution and upcoming clinical milestones critical to realizing this potential.
Industry Read-Through
Coherus’ experience underscores the challenges and opportunities in commercializing novel immuno-oncology agents in rare cancers. The importance of guideline incorporation, physician education, and salesforce optimization is evident for driving adoption in niche indications. Additionally, the clinical validation of selective Treg depletion via CCR8 targeting may catalyze broader interest in this emerging immuno-oncology subclass, influencing competitor pipelines and partnership strategies across the sector. The company’s partnership-driven label expansion model also offers a capital-efficient blueprint increasingly adopted in oncology drug development.